Discover the press release issued on April 16, 2025.

In the first quarter of 2025, revenue recorded solid growth of +4.9% at constant exchange rates and scope

●    Very strong revenues increase of 13.6% at constant exchange rates, driven by:
      ○  dynamic organic growth (+7.5%) 
      ○  strategic contribution of our acquisitions (+6.1%)

●    2024 operating income2 at an all-time high of 16.6% of revenues (16.0% excluding
      acquisitions)
      ○  up by 1.5 percentage points compared to 2023 

●    Positive trend for 2025
      ○  sales growth expected between 4% and 6% at constant exchange rates and scope
      ○  operating income relatively stable at around 16%, excluding the impact of acquisitions

Strong annual revenue growth of +13.6% supported by dynamic organic growth (+7.5%) and the strategic contribution of our acquisitions (+6.1%)

On December 2, we finalized the acquisition of Turkish company Mopsan, specialized in the distribution of petfood and companion animal health products.

Strong revenue growth as of the end of September at +12.6% and +8.6% at constant exchange rates and scope. 2024 targets maintained.

The board of directors announces a capital reduction through cancellation of treasury shares

Virbac's board of directors sets out the terms of Sébastien Huron's departure as chief executive officer

●    Exceptional business momentum in the first half, with revenue up 16.1% at constant exchange rates

●    Strong growth in adjusted current operating income1 
      ○ +3.4 points compared with 2023 to reach a record level at 21.4% of revenue

●    2024 targets confirmed  
      ○    Revenue growth expected between 7% and 9% at constant exchange rates and scope
      ○    Adjusted current operating income1 expected to be around 16% compared with 15.1% in 2023

Exceptional first-half momentum (+16.2% at constant exchange rates) driven by all regions

Exceptional first-half growth and guidance raised for 2024

Virbac finalizes minority shares’ acquisition of Globion, an Indian poultry vaccines specialistOn June 21, we finalized the acquisition of Globion's minority shares, bringing our stake to 100%. As planned, this transaction follows the acquisition of a 74% majority stake concluded on November 1, 2023.

Building on the momentum of the second half of 2023, strong first-quarter revenue growth of +10.8% at constant exchange rates

On April 1, we successfully completed the acquisition of Sasaeah. This strategic acquisition brings Virbac a leadership position in the farm animal vaccines market in Japan, notably in the cattle segment, and a large portfolio of pharmaceutical products for all the major species.

●    Revenue up 4.9%, enabling market share gains despite difficulties in 2023

●    2023 operating profitability¹ at an all-time high of 23.2% of revenue
     ○ Up 0.4 points compared to 2022 

●    Strong momentum expected in 2024
     ○  Expected revenue growth of 4% to 6% at constant exchange rates and scope
     ○  Operating profitability¹ expected to rise by 0,5 point
 

Virbac announces that it has signed a definitive agreement with ORIX Corporation for the acquisition of its animal health subsidiary Sasaeah for an enterprise value of approximately €280 million.

Annual revenue growth of +4.9% thanks to record fourth-quarter activity at +11.5%

On November 1, we successfully finalized the acquisition of a majority stake in Globion. This transaction will bolster our position of animal health leader in India by extending Virbac India’s existing poultry portfolio to the growing segment of avian vaccines. 

Revenue growth at the end of September at +2.8% at constant exchange rates and scope thanks to a strong activity rebound in the third quarter (+7.8% at constant exchange rates and scope).

Virbac announces the signing of an agreement to acquire Globion, a leading Indian poultry vaccines specialist. This transaction will bolster our position of animal health market leader in India by extending Virbac India’s existing poultry portfolio to the growing segment of avian vaccines.

Current operating income before R&D slightly improving throughout first half of 2023 in percentage of revenue

Following the decision of the board of directors on June 19, 2023 and its approval by the shareholder’s meeting, we are going to buy back 100,000 of our own shares (less than 1.25% of the capital). Main objective: to decrease the company's share capital by canceling treasury shares purchased.

At the end of August, with our priority systems fully restored and functional following the June cyberattack, we will be able to publish our mid-year results on September 28 with a two-week delay.

Revenue up about 2% during the second quarter and stable at the end of June despite two unfavorable one-off effects throughout the semester

Virbac reassesses its 2023 growth and Adjusted EBIT¹ forecast

Slight decline in first-quarter revenue primarily due to a base effect as well as a context of market slowdown

2022 current operating income on the rise at +8.3%, reflecting the momentum of our business over the year in a slowing market

Annual revenue growth of +9.6% at comparable exchange rates and scope (+14.3% at real rates), driven by exceptional business activity in the fourth quarter

Revenue growth at end of September at +7.7% at comparable exchange rates and perimeter (+12.7% at actual rates)

Increase in operating income in the first half of 2022 reflecting the dynamism of our business

Growth in revenue in the first half of 2022 of +12.0% at comparable exchange rates (+16.4% at real rates), driven by good performance in all areas

Very strong growth in revenue in the first quarter of 2022 of +16.2% at comparable exchange rates (+19.3% at real rates), driven by good performance in all areas

2021 operating profit from ordinary activities showed very strong growth, reflecting the excellent dynamism of our business in a rapidly growing market

Exceptional growth in annual revenue of +18.4% at comparable exchange rates and scope (+14.9% at constant rates and real scope), driven by remarkable performance in a very buoyant market

Virbac's first steps into the U.S. food producing animal market.

Virbac announces the acquisition of the remaining minority shares of the Centrovet group.

Excellent revenue growth of 21.2% at the end of September at comparable exchange rates and scope (+16.4% at constant rates and real scope), driven by a very solid third-quarter performance again in all areas

Virbac and Jectas Innovators are proud to announce the signature of a collaborative agreement for the development of animal health vaccine(s).

Significant increase in operating profit from ordinary activities for the first half of 2021 due to the sound market performance and dynamism of our business

Virbac announces the acquisition of additional shares in the Centrovet group.

Exceptional increase in revenue in the first half of 2021, with +21.3% at comparable exchange rates and scope (+14% at constant exchange rates and actual scope), driven by very solid performance in all areas and good market dynamics

As part of its 2030 vision, Virbac completed the acquisition of iVet LLC, a specialty petfood company. This acquisition, in addition to the portfolio of products, will bring us expertise in distribution, logistics and e-commerce which are part of the key to the success of our petfood ambition in the USA.

2021 Outlook

Virbac, today announced the successful completion of its divestment of the production plant located in Magny-en-Vexin to FC France SAS, a subsidiary of Friulchem SpA and Finest SpA. 

As a non-voting advisor, his role will be mainly to support the good governance of our company by strengthening the complementarity of the skills of the board of directors.

Very strong growth in revenue in the first quarter of 2021 at +22.6% at comparable exchange rates and scope (+12.3% at constant rates), driven by very solid performance in all areas
 

2020 current operating income showed strong growth (+37.6% at constant rates and scope), reflecting the excellent evolution of revenue (+5.7% at constant rates and scope) and a sharp decrease in expenses in the context of the Covid-19 crisis

2020 annual revenue shows strong growth of +5.7% at constant exchange rates and scope (+3.2% at constant rates) 

Revenue grew +6.8% at constant exchange rates and scope at the end of September 2020 (+5.6% at constant rates) thanks to solid third quarter performance

Virbac will change its governance at its shareholders' meeting on December 15

Operating profit from ordinary activities up sharply for the first half of 2020 reflecting revenue resiliency and strong expenditure restraint during the Covid-19 crisis

Revenue grew by +5.0% at constant exchange rates in the first half of 2020 (+4.5% excluding Sentinel), impacted by a decline in the second quarter of the year

Virbac completes divestment of U.S. Rights to SENTINEL^® brands to MSD Animal Health

Virbac to divest U.S. Rights to SENTINEL^® brands to MSD Animal Health

2020 first quarter revenue rose by +14.3% at comparable exchange rates, significantly impacted by anticipatory buying

2019 operating profit from ordinary activities on the rise

2019 annual revenue shows strong growth of +6.6% at constant exchange rates

Solid +8.4% growth in revenue at constant exchange rates at the end of September, 2019

Following the quarterly review of its indices, the Paris stock exchange operator, Euronext, includes Virbac in the CAC Mid 60 and SBF 120 as from 23 September.

Operating profit on the rise in the first half of 2019

Virbac announces the arrival of Cyrille Petit as a member of the supervisory board as of June 18, 2019. In addition, on the audit committee he will replace Olivier Bohuon, who is also a member of the supervisory board.

2019 first half-year revenue grew by +6.6% at constant exchange rates

2019 first quarter revenue rose by +10.9% at comparable exchange rates

2018 operating profit from ordinary activities grew by 13.4%

2018 annual revenue grew by +4.5% at constant exchange rates

Revenue grew by +5.5% at constant exchange rates at the end of September 2018

Operating profit up sharply in the first half of 2018

Revenue grew by +4.3% at constant exchange rates in the second quarter of 2018

2018 first quarter revenue rose by +3.3% at comparable exchange rates

Operating profit from ordinary activities 2017 comparable to 2016

Annual sales comparable to 2016 at constant exchange rates after strong fourth-quarter growth

By mutual agreement, Virbac and the other shareholders of Centrovet have decided to postpone the option to buy the Chilean aquaculture specialist for three years, under the same pricing conditions.

Virbac: quarterly sales affected by distributor destocking in the United States

On September 5, 2017, Virbac’s supervisory board co-opted Solène Madelpuech into the supervisory board as a new member. On the same day, Jeanine Dick, aged 81, announced her resignation. 

Slight increase in first half results

Virbac: second quarter sales growth largely offsets the decline in the first quarter

First quarter 2017 sales down, strongly impacted by stock effects in the distribution in the United States

Strong rebound in profitability in 2016  

Annual sales growth of 4.5%, at constant exchange rates

Virbac announces that it has received from the Food and drug administration (FDA) a communication confirming the lifting of the Warning Letter received in December 2015 for its St. Louis production site (Missouri, USA).

Sales grow by 3.2% at the end of September at constant rates

Growth of half-year results

Sales growth by 3.6% at constant exchange rates in the first half

Sales in the first quarter 2016 : return to organic growth

2015 annual results heavily impacted by the United States

Annual sales growth of 10.2%, driven by exchange rates and acquisitions

Virbac : sales grow by 5.5% in the third quarter

Half-year results  heavily impacted by the United States

Virbac : sales grow by 18.1% in the first half

Group’s perspectives for 2015 impacted by the industrial situation in the United-States

Sales growth of 17.1% in the first quarter

Virbac, listed on Euronext Paris

Results grow in 2014 following a strong second half

Sustained growth in the fourth quarter

Virbac announces the successful closing on January 2nd of its agreement with Eli Lilly and Company to acquire two major parasiticides for dogs in the United States: SENTINEL^® Flavor Tabs^® and SENTINEL^® SPECTRUM^®, marketed up to now by Novartis Animal Health.

Virbac announces that it has entered into an agreement with Eli Lilly and Company to acquire major United States veterinary products currently marketed by Novartis Animal Health. Eli Lilly has agreed to divest these U.S. assets in connection with the U.S. Federal Trade Commission’s review of Eli Lilly’s pending acquisition of Novartis Animal Health worldwide.

Confirmation of the rebound of growth in the third quarter

Half-year results impacted by foreign exchange and the low level of activity in the United States

Organic growth of 3% in the first half

Current operating profit increases by 6.9% in 2013

Rebound of growth in the last quarter

Slight rebound of organic growth in the third quarter

Slight increase of the current operating profit in the first half of 2013

Sales growth of 9.4% in the second quarter

Sales growth of 3.6% in the first quarter

A 15.8% net profit increase in 2012

Sales growth of 11.5% in 2012